Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia§

Authors

  • Betty K. Hamilton,

    1. Department of Hematologic Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Search for more papers by this author
  • Edward A. Copelan

    Corresponding author
    1. Department of Hematologic Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
    • 9500 Euclid Avenue, Cleveland, Ohio 44195, USA

    Search for more papers by this author
    • Telephone: 216-445-5647; Fax: 216-444-9464


  • Author contributions: B.K.H.: manuscript writing; E.A.C.: manuscript writing and final approval of manuscript.

  • Disclosure of potential conflicts of interest is found at the end of this article.

  • §

    First published online in STEM CELLSEXPRESS May 31, 2012.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with acute myeloid leukemia (AML). Our understanding of the biology of leukemic stem cells has continued to improve over the last decade and risk stratification using cytogenetics and molecular markers have improved our ability to select patients who would benefit from allogeneic transplantation. Results of HSCT have also improved substantitally, extending the potential application of allogeneic transplant to more patients. This review discusses the theoretical aspects of transplant, analyzes clinical results, and provides recommendations for the use of HSCT in AML. Further study of the biology of leukemic stem cells and the role for HSCT is necessary to optimize outcomes in AML patients. STEM CELLS2012;30:1581–1586

Ancillary